Insulet: Stifel cuts to hold from buy, lowers target price to $165 from $180
PODD•Stifel cut its rating on Insulet to hold from buy and lowered its target price to $165 from $180.
Related News

Salesforce: BTIG cuts target price to $250 from $300
CRM•

Hyperscale Data declares monthly dividend of $0.2708333 per Series D preferred share
GPUS•

Ducommun CFO participates in Goldman Sachs Industrials and Materials Conference
DCO•

BMO raises BILL Holdings target price to $68 from $56
BILL•

Pfizer signs licensing deal with Starna Therapeutics for autoimmune disease treatments
PFE•